<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038012</url>
  </required_header>
  <id_info>
    <org_study_id>GYN97-310</org_study_id>
    <nct_id>NCT00038012</nct_id>
  </id_info>
  <brief_title>rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin</brief_title>
  <official_title>A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved With Thrombosol and 2% DMSO in Patients With Gynecologic Malignancy Receiving Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LifeCell</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved with
      ThromboSol and 2% DMSO in Patients with Gynecologic Malignancy Receiving Carboplatin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Continuous</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Neoplasms, Gynecologic</condition>
  <arm_group>
    <arm_group_label>rhTPO-Derived Autologous Platelets Transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thrombopoietin</intervention_name>
    <arm_group_label>rhTPO-Derived Autologous Platelets Transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet-pheresis</intervention_name>
    <arm_group_label>rhTPO-Derived Autologous Platelets Transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>rhTPO-Derived Autologous Platelets Transfusion</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients with gynecologic malignancy for whom treatment with carboplatin is indicated.

          -  Age &gt;/= 15 years.

          -  Adequate hematologic, renal, and hepatic functions.

          -  Life expectancy &gt;/- 3 months. Karnofsky Performance Status &gt;/= 80.

          -  Signed informed consent form.

        EXCLUSION CRITERIA:

          -  Patients with rapidly progressive disease.

          -  Pregnant or lactating women.

          -  Patients with comorbid condition which renders patients at high risk of treatment
             complication.

          -  History of CNS metastasis.

          -  Patients with significant cardiac disease (NYHA Class III or IV), dysrhythmia, or
             recent history of MI or ischemia, transient ischemic attack or CVA within the 6 months
             of study entry.

          -  Prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of
             myeloid (G-CSF or GM-CSF) growth factors within 2 weeks or erythropoietin within 4
             weeks.

          -  Use of any nitrosourea (BCNU, CCNU) or mitomycin - C within 6 weeks.

          -  Prior surgery or RT within 2 wks of study entry.

          -  Patients with history of prior high dose chemotherapy with stem cell transplant or
             with history of prolonged thrombocytopenia (&gt; 2 weeks).

          -  History of leukemia.

          -  History of any platelet disorders including ITP, TTP or bleeding disorders.

          -  History of &gt; 3 prior chemotherapy regimens (all platinum regimens will be counted as 1
             regimen).

          -  Demonstrated lack of response to platinum-based therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2002</study_first_submitted>
  <study_first_submitted_qc>May 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2002</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-intensified carboplatin</keyword>
  <keyword>autologous cryopreserved platelets</keyword>
  <keyword>thrombopoietin</keyword>
  <keyword>Gynecologic malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

